Macrocyclic Factor VIIa Inhibitors Selective Anticoagulant Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current factor VIIa inhibitors for treating thromboembolic disorders often lack selectivity and improved pharmacological characteristics, such as enhanced inhibitory activity, selectivity, and reduced side effects, and there is a need for novel non-peptide inhibitors with better pharmacokinetic and pharmaceutical properties.
Innovation Solution
Development of novel macrocyclic derivatives and their analogues as selective inhibitors of serine protease coagulation factor VIIa, including stereoisomers, tautomers, pharmaceutically acceptable salts, and solvates, which are used in pharmaceutical compositions for treating thromboembolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current factor VIIa inhibitors are used, then anticoagulant effect is achieved, but selectivity and pharmacological characteristics are insufficient
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of factor VIIa inhibitors from peptide-based to macrocyclic non-peptide structures. This structural parameter change enhances selectivity for factor VIIa while improving pharmacokinetic properties including metabolic stability, oral bioavailability, and half-life, thereby resolving the contradiction between reliability and adaptability
Solution Approach 2:
The invention creates composite molecular structures combining macrocyclic cores with specific functional groups and side chains. This composite approach allows simultaneous optimization of selectivity through targeted binding interactions and pharmacological characteristics through controlled solubility, permeability, and metabolic stability
2Productivity
If non-peptide inhibitors are developed, then pharmacokinetic properties are improved, but inhibitory activity and selectivity may be reduced
Solution Approach 1:
The patent applies local quality by designing macrocyclic inhibitors with specific functional groups positioned at precise locations to maintain high inhibitory activity and selectivity for factor VIIa. The macrocyclic structure provides a rigid framework with localized flexible regions that can adapt to the protease active site, ensuring strong binding while maintaining improved pharmacokinetic properties
Solution Approach 2:
The transition from peptide to macrocyclic non-peptide structure represents a fundamental parameter change that simultaneously improves pharmacokinetic properties (metabolic stability, oral bioavailability) while maintaining or enhancing inhibitory activity through optimized molecular recognition interactions with factor VIIa
3Reliability
If factor VIIa inhibition is enhanced, then anticoagulant efficacy is improved, but side effects may increase
Solution Approach 1:
The patent utilizes parameter changes by developing macrocyclic inhibitors with optimized structural parameters that enhance factor VIIa selectivity. This selective binding to factor VIIa while sparing other coagulation factors (such as thrombin and factor Xa) allows potent anticoagulant efficacy with reduced side effects including bleeding complications
Solution Approach 2:
The macrocyclic inhibitor acts as a selective intermediary that specifically interrupts the factor VIIa-tissue factor complex formation and activity. This targeted interference prevents excessive coagulation activation without broadly affecting the coagulation cascade, thereby achieving efficacy with minimal side effects
Data Source
AI summary
The present invention relates generally to novel macrocycles of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, thereof, wherein the variables A, B, L, M, W, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. These compounds are selective inhibitors of the serine protease coagulation factor VIIa which can be used as medicaments.